Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in <i>EGFR</i> -altered non-small-cell lung cancer

Natasha B. Leighl, Antonio Passaro, Hiroaki Akamatsu, Alexander I. Spira, Danny Nguyen, Angel Qin, Julia Schuchard, Mohamed Gamil, Mahadi Baig, Mariam Alexander

Open source

DOI: 10.1080/14796694.2026.2709936
Published: 2026-08-09
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2709936,
  title = {Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in
                    <i>EGFR</i>
                    -altered non-small-cell lung cancer},
  author = {Natasha B. Leighl and Antonio Passaro and Hiroaki Akamatsu and Alexander I. Spira and Danny Nguyen and Angel Qin and Julia Schuchard and Mohamed Gamil and Mahadi Baig and Mariam Alexander},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2709936},
  url = {https://doi.org/10.1080/14796694.2026.2709936}
}

RIS

TY  - JOUR
TI  - Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in
                    <i>EGFR</i>
                    -altered non-small-cell lung cancer
AU  - Natasha B. Leighl
AU  - Antonio Passaro
AU  - Hiroaki Akamatsu
AU  - Alexander I. Spira
AU  - Danny Nguyen
AU  - Angel Qin
AU  - Julia Schuchard
AU  - Mohamed Gamil
AU  - Mahadi Baig
AU  - Mariam Alexander
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2709936
UR  - https://doi.org/10.1080/14796694.2026.2709936
ER  -

APA

Leighl, N. B., Passaro, A., Akamatsu, H., Spira, A. I., Nguyen, D., Qin, A., Schuchard, J., Gamil, M., Baig, M., & Alexander, M. (2026). Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in <i>EGFR</i> -altered non-small-cell lung cancer. Future Oncology. https://doi.org/10.1080/14796694.2026.2709936

Source records

crossref · retrieved 2026-11-10T20:43:18.065Z